论文部分内容阅读
为了解国产西替利嗪治疗常年性变应性鼻炎（PAR）的疗效及副反应，以双盲法随机将203例PAR病人分为两组：进口组：用比利时UCB公司产西替利嗪片（商品名仙特敏）；国产组：用深圳市医药研究设计院及广东彼迪药业有限公司研制的西替利嗪片进行治疗。经治1～2个疗程后发现，两组在症状、体征达到有效改善时间基本相同；临床疗效总有效率：国产组为86．49％，进口组为86．96％；副反应发生率：国产组为18．02％，进口组为15．22％。经卡方检验，两组差异无显著性意义（P＞0．05）。表明：国产西替利嗪在治疗PAR上是安全、有效的。
To understand the efficacy and side effects of domestic cetirizine in the treatment of perennial allergic rhinitis (PAR), 203 patients with PAR were randomly divided into two groups by double-blind method: Import group: Tablets (trade name Xian Temin); domestic group: with Shenzhen Medical Research and Design Institute and Guangdong Petit Pharmaceutical Co., Ltd. developed cetirizine tablets for treatment. The treatment of 1 to 2 courses found that the two groups in the symptoms and signs of effective improvement time is basically the same; the total effective rate of clinical efficacy: the domestic group was 86.49%, the import group was 86.96%; the incidence of side effects: 18.02% for the domestic group and 15.22% for the import group. The chi-square test, no significant difference between the two groups (P> 0.05). Show: domestic cetirizine in the treatment of PAR is safe and effective.